Senescent cells

A novel therapeutic target for aging and age-related diseases

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Aging is the main risk factor for most chronic diseases, disabilities, and declining health. It has been proposed that senescent cells - damaged cells that have lost the ability to divide - drive the deterioration that underlies aging and age-related diseases. However, definitive evidence for this relationship has been lacking. The use of a progeroid mouse model (which expresses low amounts of the mitotic checkpoint protein BubR1) has been instrumental in demonstrating that p16 Ink4a -positive senescent cells drive age-related pathologies and that selective elimination of these cells can prevent or delay age-related deterioration. These studies identify senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. Here, we describe how senescent cells develop, the experimental evidence that causally implicates senescent cells in age-related dysfunction, the chronic diseases and disorders that are characterized by the accumulation of senescent cells at sites of pathology, and the therapeutic approaches that could specifically target senescent cells.

Original languageEnglish (US)
Pages (from-to)105-116
Number of pages12
JournalClinical Pharmacology and Therapeutics
Volume93
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Therapeutics
Chronic Disease
Pathology
M Phase Cell Cycle Checkpoints
Health
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Senescent cells : A novel therapeutic target for aging and age-related diseases. / Naylor, R. M.; Baker, Darren J; Van Deursen, Jan.

In: Clinical Pharmacology and Therapeutics, Vol. 93, No. 1, 01.2013, p. 105-116.

Research output: Contribution to journalArticle

@article{4e53d972a21748beb05fc74cf11ccbdd,
title = "Senescent cells: A novel therapeutic target for aging and age-related diseases",
abstract = "Aging is the main risk factor for most chronic diseases, disabilities, and declining health. It has been proposed that senescent cells - damaged cells that have lost the ability to divide - drive the deterioration that underlies aging and age-related diseases. However, definitive evidence for this relationship has been lacking. The use of a progeroid mouse model (which expresses low amounts of the mitotic checkpoint protein BubR1) has been instrumental in demonstrating that p16 Ink4a -positive senescent cells drive age-related pathologies and that selective elimination of these cells can prevent or delay age-related deterioration. These studies identify senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. Here, we describe how senescent cells develop, the experimental evidence that causally implicates senescent cells in age-related dysfunction, the chronic diseases and disorders that are characterized by the accumulation of senescent cells at sites of pathology, and the therapeutic approaches that could specifically target senescent cells.",
author = "Naylor, {R. M.} and Baker, {Darren J} and {Van Deursen}, Jan",
year = "2013",
month = "1",
doi = "10.1038/clpt.2012.193",
language = "English (US)",
volume = "93",
pages = "105--116",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Senescent cells

T2 - A novel therapeutic target for aging and age-related diseases

AU - Naylor, R. M.

AU - Baker, Darren J

AU - Van Deursen, Jan

PY - 2013/1

Y1 - 2013/1

N2 - Aging is the main risk factor for most chronic diseases, disabilities, and declining health. It has been proposed that senescent cells - damaged cells that have lost the ability to divide - drive the deterioration that underlies aging and age-related diseases. However, definitive evidence for this relationship has been lacking. The use of a progeroid mouse model (which expresses low amounts of the mitotic checkpoint protein BubR1) has been instrumental in demonstrating that p16 Ink4a -positive senescent cells drive age-related pathologies and that selective elimination of these cells can prevent or delay age-related deterioration. These studies identify senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. Here, we describe how senescent cells develop, the experimental evidence that causally implicates senescent cells in age-related dysfunction, the chronic diseases and disorders that are characterized by the accumulation of senescent cells at sites of pathology, and the therapeutic approaches that could specifically target senescent cells.

AB - Aging is the main risk factor for most chronic diseases, disabilities, and declining health. It has been proposed that senescent cells - damaged cells that have lost the ability to divide - drive the deterioration that underlies aging and age-related diseases. However, definitive evidence for this relationship has been lacking. The use of a progeroid mouse model (which expresses low amounts of the mitotic checkpoint protein BubR1) has been instrumental in demonstrating that p16 Ink4a -positive senescent cells drive age-related pathologies and that selective elimination of these cells can prevent or delay age-related deterioration. These studies identify senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. Here, we describe how senescent cells develop, the experimental evidence that causally implicates senescent cells in age-related dysfunction, the chronic diseases and disorders that are characterized by the accumulation of senescent cells at sites of pathology, and the therapeutic approaches that could specifically target senescent cells.

UR - http://www.scopus.com/inward/record.url?scp=84871302192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871302192&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.193

DO - 10.1038/clpt.2012.193

M3 - Article

VL - 93

SP - 105

EP - 116

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -